距离5月初医药流通布局“十二五”规划的正式公布还不到半年,中国医药商业巨头间的竞争已呈现白热化趋势。继华润控股北药集团之后,上海医药也转变增长模式,试图与外资企业合作。一场无硝烟的医药商业竞争拉锯战正在中国全面上演。 Less than half a year has passed since the official announcement of the distribution plan for pharmaceutical distribution in the beginning of May and the 12th Five-Year Plan, the competition among China’s pharmaceutical giants has turned white hot. After China Resources Holdings North Pharmaceutical Group, Shanghai Pharmaceuticals also changed its growth model and tried to cooperate with foreign companies. A drug-free competition in pharmaceutical commercials is being staged in China.